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Rimonabant, a selective cannabinoid-1 (CB1) receptor antagonist, has been shown to reduce weight and enhance improvements
in cardiometabolic risk parameters in Western populations. This study assessed these eﬀects of rimonabant in Asian population.
A total of 643 patients (BMI 25kg/m2 or greater without diabetes) from China, Republic of Korea, and Taiwan were prescribed a
hypocaloric diet (600kcal/day deﬁcit) and randomized to rimonabant 20mg (n = 318) or placebo (n = 325) for 9months. The
primary eﬃcacy variable was weight change from baseline after 9 months of treatment. Results showed that rimonabant group
lost more weight than placebo, (LSM ± SEM of −4.7 ± 0.3kg vs. −1.7 ± 0.3kg, P<. 0001). The 5% and 10% responders were 2
or 3 folds more in the rimonabant group (53.0% vs. 20.0% and 21.5% vs. 5.7%, resp.) (P<. 0001). Rimonabant also signiﬁcantly
increased HDL-cholesterol, decreased triglycerides and waist circumference,by 7.1%, 10.6%, and 2.8cm, respectively (P<. 0001).
This study conﬁrmed the comparable eﬃcacy and safety proﬁle of rimonabant in Asian population to Caucasians. Owing to the
recent suspension of all the CB1 antagonists oﬀ the pharmaceutical market for weight reduction in Europe and USA, a perspective
in drug discovery for intervening peripheral CB1 receptor in the management of obesity is discussed.
1.Introduction
Overweight and obesity, a global phenomenon, aﬀects more
than 1 billion adults, with 300 million being clinically obese
[1]. With changing life styles and dietary patterns, obesity
is rapidly increasing in epidemic proportions globally. In
the national nutritional surveys of the 3 countries that
participated in the RIO-Asia study, the obesity prevalence
rates were at 14.7% in China [2], 26.6% in Taiwan [3], and
30.6% in Korea [4] in the year 2001-2002.
Obesity is a complex metabolic disorder characterized by
an imbalance in energy homeostasis [5], abnormal devel-
opment of adipose tissue, and deregulation of hormones
and cytokines including adipocytokines [6]. This chronic
metabolic imbalance is associated withcomorbidities suchas
cardiovascular disorders [7], hypertension [8], sleep apnea
[9], diabetes mellitus [1], and certain types of cancer
[10] and related morbidity/mortality. Besides weight loss
and favorable cardiometabolic proﬁle [11], pharmacolog-
ical interventions for obesity should address reduction in
abdominal obesity and lower the risk of developing diabetes
mellitus.
G protein-coupled cannabinoid receptor, CB-1 of the
endocannabinoid system (ECS), plays a crucial role in regu-
lating feeding pattern, lipid metabolism, and energy home-
ostasis. CB-1 receptors are located in the central nervous
systemandperipheraltissuesincludingadipocytes,pancreas,
gut, liver, and muscle [12]. Rimonabant is a selective CB-1
antagonist drug to be developed for weight loss. Results of in
vitro experiments have suggested the involvement of fourth
and ﬁfth transmembrane domains of the CB-1 receptor for
high-aﬃnity binding of rimonabant [13, 14]. Rimonabant2 Journal of Obesity
has been shown to exert a peripheral eﬀect on food intake by
regulating Acrp30 (i.e., adiponectin) and insulin, hormones
involved in lipid and glucose metabolism, respectively [5].
The mechanism of the long-lasting weight loss through
rimonabant may be associated with an increase in energy
expenditure and/or metabolic activities [5, 15].
Animal studies [16, 17]a n dh u m a nt r i a l sh a v ed e m o n -
strated the eﬃcacy of rimonabant in inducing weight loss
and improving dyslipidemia and insulin sensitivity. The
RIO-Europe [18] and RIO-North America [19] clinical trials
studied the weight loss in obese or overweight Caucasians
treatedwith20mgrimonabant.Attheendofa1-yearperiod,
the weight loss was signiﬁcantly greater in patients treated
with rimonabant (−6.3 to −6.6kg; P<. 001 versus placebo,
−1.6 to −1.8kg). The proportion of patients who achieved
5% or greater decrease in body weight was 48.6–50.9% while
a 10% or greater decrease was noted in 25.2–27.4% patients.
Areductioninwaistcircumference(3.6cm)andtriglycerides
(13.2%), as well as an increase in HDL-cholesterol (7.2%),
was also observed in the rimonabant group. After 2 years
of treatment with 20mg rimonabant, the weight loss was
maintained at 7.4kg. Similar results were observed in
the RIO-Lipid study [20] which analyzed the eﬃcacy of
rimonabant 20mg in overweight or obese Caucasians with
dyslipidemia. A signiﬁcant suggestion of the study was that
in addition to weight reduction, rimonabant also mobilized
abdominal fat and improved cardiovascular risk proﬁle.
Furthermore, although the adiponectin-elevating eﬀect was
indirect, it was independent of weight loss.
The eﬃcacy of rimonabant in Asian ethnicity has not yet
been evaluated. Evidence shows that the incidence of obesity
is increasing rapidly in Asian countries [1, 21, 22]. As stated
above, Asian populations have a greater body fat content at
a lower body mass index (BMI) compared with Caucasians
[23, 24]. Consequently, obesity-related metabolic disorders
like dyslipidemia, hypertension, and type 2 diabetes are
more frequently observed at lower BMI in Asians than in
Caucasians [22]. Hence, the WHO has redeﬁned the classi-
ﬁcation of obesity based on BMI in Asians. The BMI cutoﬀ
was lowered in Asians to ≥23.0kg/m2 for overweight and
≥25.0kg/m2 for obesity compared to 25–30kg/m2 for over-
weight and ≥30 kg/m2 for obesity in Caucasians [1, 22, 25].
The RIO-ASIA study evaluated the eﬃcacy and safety of
rimonabant20mg,alongwithahypocaloricdiet,inreducing
weight and improving cardiometabolic risk factors in obese
Asian population.
2. Methods and Procedures
2.1. Study Design. This phase 3, randomized, double-blind,
placebo-controlled, parallel-group, multinational study was
carried out in 32 centers in China (n = 240), Republic of
Korea (n = 200), and Taiwan (n = 203) between April 2006
and April 2007.
After a screening period of 7 to 14 days, obese patients
were randomized in a 1:1 ratio to treatment with rimon-
abant 20mg (n = 318) once daily or placebo (n = 325)
for a 9-month period. Randomization was stratiﬁed based
on BMI status at baseline as 25 to 27kg/m2 or >27kg/m2.
Follow-up visits were scheduled every 28 days throughout
the study duration. Study participants were prescribed at
baselineahypocaloricdietforthestudyduration.Thecalorie
requirement was calculated based on basal metabolism rate
andphysicalactivity,fromwhich600kcal/daywassubtracted
to calculate the recommended diet. A food intake assessment
was carried out on day 84, day 168, and day 252 from diet
diary entries. The protocol, approved by the Institutional
Review Boards/Ethics Committees for each centre, was
conducted in compliance with the Helsinki Declaration and
withanindependent,unblindeddatamonitoringcommittee.
All patients provided written informed consent.
2.2. Patients. Eligible patients were aged ≥18 years with
aB M I≥25kg/m2. Exclusion criteria were a body weight
ﬂuctuationofatleast5kgintheprevious3months,asystolic
blood pressure >165mmHg and/or diastolic blood pressure
>105mmHg at screening and baseline, presence of type 1
or type 2 diabetes, presence of any clinically signiﬁcant dis-
orders(endocrine/metabolic/neurological/psychologicaldis-
orders; presence/history of cancer).
2.3. Measures and Assessments. The primary eﬃcacy end-
point was the absolute weight change from baseline (ran-
domization)to9monthsintheintent-to-treat(ITT)popula-
tion. Secondary eﬃcacy endpoints were waist circumference
(as a marker of change in abdominal obesity), high-density
lipoprotein (HDL)-cholesterol, triglycerides, fasting insulin,
and glucose.
Measurement of body weight was carried out at each
visit using a calibrated scale. Based on established protocol
[26], 3 waist measurements were taken in centimeters at
the midpoint between the lower rib margin and the iliac
crest. The variations in these measurements were expected
to be ≤1.0cm. Failure to ﬁt within these criteria would
leadtoafourthmeasurement.Metabolicparameters,includ-
ing glucose, insulin, glycosylated hemoglobin (HbA1c),
total cholesterol, low-density lipoprotein (LDL)-cholesterol,
HDL-cholesterol, and triglycerides, were measured under
fastingconditionsonday84,day168,andday252inacentral
laboratory. Safety assessments consisted of spontaneously
reported adverse events, clinical examinations, laboratory
tests, vital signs, and electrocardiograms.
2.4. Statistical Analysis. T h es a m p l es i z ec a l c u l a t i o n sf o r
the study were derived from the RIO-Europe study and
were based on a test to compare the mean change in
weight (primary variable) and HDL-cholesterol (secondary
conﬁrmatory variable) from baseline between the 2 groups.
The calculations of sample sizes were done using the sample
size software nQuery Advisor 4.0. Thus with a standard
deviation (SD) of 6.5kg, 200 randomized patients (100
patients/group) were required to detect a mean treatment
diﬀerence of 3kg in weight. For HDL-cholesterol change,
with a common SD of 25%, 414 randomized patients (207
patients/group) were required to detect a mean treatment
diﬀerence of 8% in HDL-cholesterol. Finally, to fulﬁll the
country/region requirements for the number of exposedJournal of Obesity 3
Patients screened,
N = 819
Patients randomized,
N = 643
Patients randomized
and exposed,
N = 642
Screen failures,
N = 176
Patients who did not
receive double-blind
treatment, N = 1a
Placebo, N = 324
Stratum: BMIb
<25kg/m2, n = 1
25 to 27kg/m2, n = 69
>27kg/m2,n = 254
Rimonabant 20mg, N = 318
Stratum: BMIb
<25kg/m2, n = 1
25 to 27kg/m2, n = 70
>27kg/m2, n = 247
Completed
treatment,
N = 265
Completed
treatment,
N = 285
Discontinued treatment, n = 59
Adverse event, n = 9
Poor protocol compliance, n = 7
Subject’s request, n = 28
Lost to followup, n = 0
Other reasons, n = 15
Discontinued treatment, n = 33
Adverse event, n = 10
Poor protocol compliance, n = 3
Subject’s request, n = 12
Lost to followup, n = 0
Other reasons, n = 8
aOne patient who was randomized to the placebo group was not exposed to the investigational product
owing to a diagnosis of pregnancy at the time of randomization.
bBaseline BMI was used.
Figure 1: Flow of patients in RIO Asia study.
patients, a total of 640 patients had to be randomized (320
patients/group).
Statistical analysis was performed using SAS version
8.2 or higher. All statistical tests were 2-sided at the 5%
signiﬁcance level. Eﬃcacy analyses were performed in ITT
population, which consisted of all randomized patients and
was the primary population for eﬃcacy analyses.
The absolute change in body weight from baseline to
9 months was analyzed using a 3-way analysis of covari-
ance (ANCOVA) model, which included 3 ﬁxed eﬀects—
treatment, country/region, and randomization stratum—
and 1 covariate, baseline weight. Rimonabant 20mg was
compared with placebo using a Student’s t-test within the
framework of the ANCOVA model. In addition, a 95%
conﬁdence interval (CI) was constructed for the diﬀerence
in mean absolute weight changes between the groups.
P a t i e n t sw h oa c h i e v e da5 %o r1 0 %r e d u c t i o ni nb o d y
weight from baseline at 9 months were classiﬁed as 5% or
10% responders. The proportion of 5% or 10% responders
in the rimonabant 20-mg group was compared with placebo
using a logistic regression model with 3 ﬁxed eﬀects—
treatment, country/region, and randomization stratum—
and 1 covariate, baseline body weight.
Secondary eﬃcacy endpoints were analyzed at 9 months
using the ITT population. With the exception of the
lipid parameters, continuous secondary eﬃcacy endpoints
were assessed as the absolute change from baseline at 9
months. Lipid parameters, except total cholesterol/HDL-
cholesterol ratio, were assessed as relative change from base-
line and analyzed as described for the other secondary end
points.
In the eﬃcacy analyses of endpoints for the ITT popu-
lation, the last observation carried forward method (LOCF)
was used to account for missing assessments or patients who
prematurely discontinued. These endpoints were replaced by
the last available postbaseline on-treatment observation.
3. Results
3.1. Patients. A total of 643 patients were randomized (318
in the rimonabant 20mg group and 325 in the placebo
group) from 32 centers in China (n = 240), Republic4 Journal of Obesity
Table 1: Demographic characteristics and comorbidities.
Placebo
(N = 324)
Rimonabant
20mg
(N = 318)
Overall
(N = 642)
Age (years)
Overall, mean (SD) 35.3 (10.5) 36.7 (10.8) 36.0 (10.7)
Age group, n (%)
<18 0 1 (0.3%) 1 (0.2%)
[18–49] 294 (90.7%) 273 (85.8%) 567 (88.3%)
[50–64] 27 (8.3%) 41 (12.9%) 68 (10.6%)
≥65 3 (0.9%) 3 (0.9%) 6 (0.9%)
Gender, n (%)
Male 103 (31.8%) 99 (31.1%) 202 (31.5%)
Female 221 (68.2%) 219 (68.9%) 440 (68.5%)
Country, n (%)
China 121 (37.3%) 119 (37.4%) 240 (37.4%)
Republic of Korea 101 (31.2%) 99 (31.1%) 200 (31.2%)
Taiwan 102 (31.5%) 100 (31.4%) 202 (31.5%)
Comorbidities, n (%)
Hypertension 42 (13.0%) 51 (16.0%) 93 (14.5%)
Dyslipidemia 73 (22.5%) 73 (23.0%) 146 (22.7%)
of Korea (n = 200), and Taiwan (n = 203)—1 patient
randomized to the placebo group did not receive the study
treatment.Ahigherpercentageofpatients intherimonabant
20mg group (n = 285, 89.6%) completed the study
treatment period compared with the placebo group (n =
265, 81.5%) (Figure 1). 11 patients were excluded from the
ITT population (1 for nonexposure and 10 for missing
postbaseline weight assessment); thus, the ITT population
consisted of 632 patients (317 and 315 patients on placebo
and rimonabant 20mg groups, resp.). Treatment compliance
was similar in both treatment groups: 98.7% and 96.9%;
patients in the rimonabant and placebo groups, respectively,
achieved 80% treatment compliance target (data on ﬁle).
Demographic and baseline characteristics were similar
between the 2 treatment groups, with equal distribution
of patients across treatment in the 3 countries (Tables 1
and 2). 14.5% patients had hypertension, and 22.7% were
dyslipidemic. Mean age was 36 ± 10.7 years with more than
two thirds of patients being women (68.5%). Mean BMI was
30.26 ± 4.23kg/m2 with a baseline weight ranged from 54.3
to 161.5kg and a mean weight of 81.48 ± 15.67kg. Majority
of patients (78.0%) had BMI > 27kg/m2. More than one
third of patients had low HDL-cholesterol (34.1%), high
triglycerides (31.3%), and high LDL-cholesterol (32.7%),
and 17.4% had impaired fasting glucose.
3.2. Weight. In the ITT population, weight loss was signif-
icantly greater in the rimonabant group (least square (LS)
mean ± SEM: −4.7 ± 0.3) than in the placebo group (LS
mean ± SEM: −1.7 ± 0.3) at 9 months, leading to a placebo-
subtracted weight loss of approximately 3.0kg (P<. 0001)
(Figure 2(a)). When expressedas a percentage, rimonabant-
treatedpatientslost6.0%oftheirbaselinebodyweightversus
2.3% in the placebo group.
The percentage of patients who achieved at least a 5%
reduction and 10% reduction from their baseline body
weight at 9 months in the rimonabant 20-mg group (53.0%
and 20.0%, resp.) was more than 2-fold and 3-fold higher
compared with the placebo group (21.5% and 5.7%, resp.)
(P<. 0001) in the ITT population (Figure 2(b)).
Treatment with rimonabant resulted in a signiﬁcant (P<
.001) decrease in weight in both BMI strata. In patients
with BMI of 25 to 27kg/m2 and >27kg/m2, the percentage
of weight decrease was 5.61% and 6.11%, respectively, with
rimonabant 20mg while the corresponding changes in the
placebo group were 2.05% and 2.31% (Table 3 and Figure 3).
3.3. Changes in Secondary Eﬃcacy Variables. At 9 months,
the percentage change in HDL-cholesterol revealed a
steady increase in both treatment groups (Figure 4(a)).
Rimonabant increased HDL-cholesterol by 7.1% compared
with placebo (P<. 0001). Rimonabant reduced triglyceride
levels by 10.6% compared with placebo (P = .0047). The
mean waist circumference decreased from baseline by 5.93
± 0.33cm in the rimonabant 20-mg group compared with
3.2 ± 0.33cm in the placebo group (−2.8cm versus placebo;
P<. 0001) (Figure 4(c)). In this nondiabetic population,
minimal, nonsigniﬁcant changes were observed in fasting
glucose and fasting insulin in both groups at 9 months, with,
however, a favorable trend for rimonabant 20mg, especially
in fasting insulin.
3.4. Safety Events. The incidence of treatment-emergent
adverse events (TEAEs) was higher in the rimonabant groupJournal of Obesity 5
−6
−4
−2
0
2
W
e
i
g
h
t
c
h
a
n
g
e
(
k
g
)
0 4 8 1 21 62 02 42 83 23 6 L O C F
PLB: 317
R 20mg: 315
306
308
296
296
273
288
258
277
317
315
(weeks)
Placebo
Rimonabant 20mg
I
T
T
,
L
O
C
F
−
2
.
9
9
k
g
v
e
r
s
u
s
p
l
a
c
e
b
o
P
<
.
0
0
0
1
PLB
PLB
20 mg
20 mg
(a)
0
10
20
30
40
50
60
P
a
t
i
e
n
t
s
(
%
)
Placebo
n = 317
Rimonabant 20mg
n = 315
21.5%
53%
Weight loss ≥5%
0
10
20
30
40
50
60
P
a
t
i
e
n
t
s
(
%
)
Placebo
n = 317
Rimonabant 20mg
n = 315
5.7%
20%
Weight loss ≥10 %
aP<. 0001 versus placebo.
ITT, intent to treat; LOCF, last observation carried forward;
PLB, placebe; R, Rimonabant.
(b)
Figure 2: Eﬀect of rimonabant on (a) weight at each visit and at 9 months (b) 5% and 10% weight responders.
(66.0%, n = 210) compared with the placebo group
(56.8%, n = 184) (Table 4). The percentage of patients
who permanently discontinued due to TEAEs was low and
comparable between the placebo (2.8%, n = 9) and rimon-
abant (3.1%, n = 10) groups. Serious TEAEs were more
frequently reported in the placebo group compared with the
rimonabant 20mg group (4.6% versus 3.1%) with no deaths
reported during the study period. The most frequent adverse
events (≥0.5%) leading to treatment discontinuation were
dizziness in the rimonabant 20mg group (0.9% versus 0.6%
in placebo) and headache (0.6% versus 0.0% in rimonabant
20mg) in the placebo group (data on ﬁle).
In the rimonabant group (Table 4), the common adverse
events reported with a ≥2% incidence (≥1% over placebo
patients) were upper respiratory tract infections (10.7%
versus 9.0%), nausea (11.6% versus 4.0%), diarrhea (7.5%6 Journal of Obesity
Table 2: Baseline characteristics: randomized and expose patients.
Placebo (N = 324) Rimonabant 20mg (N = 318) Overall (N = 642)
Weight (kg)
Mean (SD) 82.00 (16.40) 80.95 (14.90) 81.48 (15.67)
Waist (cm)
Male, n (%)
>90cm 97 (94.2%) 92 (92.9%) 189 (93.6%)
Female, n (%)
>80cm 209 (94.6%) 211 (96.3%) 420 (95.5%)
BMI (kg/m2)
Mean (SD) 30.45 (4.41) 30.07 (4.04) 30.26 (4.23)
BMI group, n (%)
<25 1 (0.3%) 1 (0.3%) 2 (0.3%)
[25–27] 69 (21.3%) 70 (22.0%) 139 (21.7%)
>27 254 (78.4%) 247 (77.7%) 501 (78.0%)
HDL-cholesterol (mmol/L)
Mean (SD) 1.35 (0.29) 1.35 (0.29) 1.35 (0.29)
HDL-cholesterol group, n (%)
M: <1.036, F: <1.295 100 (30.9%) 119 (37.4%) 219 (34.1%)
Triglycerides (mmol/L)
Mean (SD) 1.57 (1.01) 1.59 (0.98) 1.58 (0.99)
Triglycerides group, n (%)
≥1.69 99 (30.7%) 101 (31.9%) 200 (31.3%)
LDL-cholesterol (mmol/L)
Mean (SD) 3.08 (0.72) 3.01 (0.72) 3.04 (0.72)
LDL-cholesterol group, n (%)
≥3.36 113 (34.9%) 97 (30.5%) 210 (32.7%)
Total/HDL-cholesterol
Mean (SD) 3.70 (0.96) 3.65 (0.97) 3.67 (0.97)
Fasting glucose (mmol/L)
Mean (SD) 5.07 (0.48) 5.17 (0.56) 5.12 (0.52)
Fasting glucose group, n (%)
IFG: ≥5.55 and <6.99 43 (13.4%) 68 (21.5%) 111 (17.4%)
Fasting insulin (pmol/L) 92.04 (57.41) 98.30 (158.08) 95.17 (118.8)
Mean (SD)
HbA1c (%)
Mean (SD) 5.56 (0.39) 5.61 (0.41) 5.59 (0.40)
BMI: body mass index. HDL: high-density lipoprotein. IFG: impaired fasting glucose. LDL: low-density lipoprotein. HbA1c: glycosylated hemoglobin.
versus 4.3%), dyspepsia (3.1% versus 0.6%), vomiting (2.8%
versus 0.9%), dizziness (10.7% versus 9.6%), and depression
(4.1% versus 0.9%).
4. Discussion
This 9-month RIO-Asia study showed that rimonabant
20mg is eﬀective in reducing body weight in obese Asians.
The 9-month treatment period with rimonabant was con-
sidered to be suﬃcient to compare the eﬃcacy and safety of
rimonabant with placebo, based on the results from previous
RIO studies. A signiﬁcantly greater reduction in weight was
observed in the rimonabant 20-mg groupcomparedwiththe
placebo group (−2.99kg, P<. 0001).
The percentage of patients who achieved at least 5%
(53.0%) and 10% (20%) reduction of their baseline body
weight with rimonabant treatment at 9 months was more
than twice (21.5%) and four times (5.7%) compared with
placebo. In obesity, a 5% decrease in body weight is
associated with an improved cardiometabolic proﬁle [11].
The reduction in waist circumference followed the same
pattern as body weight reduction. Obesity guidelines for
Asia-Paciﬁc have recommended a waist circumference of
≥90cm in men and ≥80cm in women [25]. Since rimon-
abant decreased the mean waist circumference by 2.8cm,
reduction in abdominal obesity would also lower the risk of
developingrelatedmetabolicdisorders.InternationalDayfor
the Evaluation of Obesity (IDEA) study established a gradedJournal of Obesity 7
Table 3: Change in weight (last observation carried forward) by BMI stratum in intent-to-treat population.
BMI: 25 to 27kg/m2 BMI: >27kg/m2
Weight (kg) Placebo (N = 74) Rimonabant 20mg (N = 71) Placebo (N = 251) Rimonabant 20mg (N = 247)
Baseline
Mean (SD) 67.42 (6.21) 69.28 (7.45) 86.19 (16.22) 84.23 (14.81)
Month 9 (LOCF)
Mean (SD) 66.06 (6.93) 65.47 (8.51) 84.20 (16.50) 79.14 (15.33)
Change from baseline
Mean (SD) −1.37 (2.95) −3.81 (3.59) −1.99 (4.55) −5.09 (5.37)
LS Mean (SEM) −1.35 (0.384) −3.84 (0.387) −2.02 (0.315) −5.18 (0.316)
LS Mean Diﬀerence (SEM) — −2.49 (0.548) — −3.16 (0.446)
95%CI — (−3.570 to −1.403) — (−4.034 to −2.283)
P value — <.0001 — <.0001
Percent change from baseline
Mean (SD) −2.05 (4.58) −5.61 (5.33) −2.31 (4.94) −6.11 (6.22)
BMI: body mass index. CI: conﬁdence interval. LS: least square. LOCF: last observation carried forward.
Table 4: Most common adverse events (≥2% in rimonabant-treated patients and ≥1% in placebo).
Placebo (N = 324) Rimonabant (20mg) (N = 318)
Patients with any TEAE 184 (56.8%) 210 (66.0%)
Patients with any serious TEAE 15 (4.6%) 10 (3.1%)
Patients with any TEAE leading to death 0 0
Patients permanently discontinued due to TEAE 9 (2.8%) 10 (3.1%)
Most common adverse events
Gastrointestinal disorders
Nausea 13 (4.0%) 37 (11.6%)
Diarrhea 14 (4.3%) 24 (7.5%)
Dyspepsia 2 (0.6%) 10 (3.1%)
Vomiting 3 (0.9%) 9 (2.8%)
Nervous system disorders
Dizziness 31 (9.6%) 34 (10.7%)
Psychiatric disorders
Insomnia 11 (3.4%) 14 (4.4%)
Depression 3 (0.9%) 13 (4.1%)
Anxiety 5 (1.5%) 12 (3.8%)
Skin and subcutaneous tissue disorders
Hyperhidrosis 3 (0.9%) 7 (2.2%)
Cardiac disorders
Palpitations 3 (0.9%) 15 (4.7%)
General disorders and administration site conditions
Fatigue 3 (0.9%) 8 (2.5%)
Infections and infestations
URTI 29 (9.0%) 34 (10.7%)
TEAE: treatment-emergent adverse event; URTI: upper respiratory tract infection.
Note: TEAEs included all adverse events with an onset date during treatment exposure and up to 75 days following the last study drug intake.
relationship between waist circumference, diabetes mellitus,
and cardiovascular disease [27].
Signiﬁcant improvements in HDL-cholesterol and
triglycerides, associated with the reduction in weight
and waist circumference, were seen in the rimonabant
20mg group compared with the placebo group (P<. 001,
P = .0047, resp.). Hence, the results of this study indicate
that treatment with rimonabant would have favourable
eﬀects on body weight and cardiometabolic risk proﬁle in
obese Asians who are known to have a greater incidence
of obesity-related metabolic disorders at a lower BMI as
compared with Caucasians [22].
The results in this RIO-Asia study are consistent with
those in the 4 previous double-blind, placebo-controlled
RIO studies (RIO-Lipids, RIO-Europe, RIO-Diabetes, and
RIO-North America) conducted in more than 6000 patients,
where rimonabant 20mg had shown a signiﬁcant reduction
in body weight at 1 year compared with placebo (P<. 0018 Journal of Obesity
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versus placebo). In Rio-Asia, the mean decrease in weight
induced by rimonabant, compared with placebo, in the
ITT population was 2.99kg which was lower than RIO-
North America (5.2kg), RIO-Europe (5.3kg), and RIO-
Lipids (6.0kg) on day 252 (data on ﬁle). The lower mean
lossinbodyweightintheRIO-Asiastudycouldbeattributed
to the lower baseline weights in Asian study population
(81.48kg) as compared with the Caucasian populations in
the other studies (93.2–102.7kg), but the percentage change
in the weight loss was comparable among the diﬀerent
studies.
In this study, similar results for weight loss was observed
across both BMI strata (25–27kg/m2 and >27kg/m2).
Rimonabant decreased weight by 5.61% in the group with
a BMI 25 to 27kg/m2 and by 6.11% in the group with a BMI
> 27kg/m2, which can lower the risk of developing related
metabolic disorders. Metabolic disorders are initiated at a
lower BMI in Asians compared with Caucasians [22]. The
BMI cut-oﬀ points for overweight and obesity are diﬀerent
in the Asian population as compared with the Caucasian
population [1, 22, 25]. In the IDEA study, which involved
177, 345 patients in 63 countries, one half to two thirds
of the study population were overweight or obese (BMI ≥
25kg/m2). The frequency of diabetes mellitus and coronary
vascular disease increased with waist circumference in all
categories of BMI (<25kg/m2, 25–30kg/m2,a n d>30kg/m2)
[27]. In adult Korean population, the incidence of diabetes,
hypertension,anddyslipidemiawas2timesmoreataBMIof
23.0 to 24.0kg/m2 and 3 times more at a BMI of 26.0kg/m2
[28]. In Chinese population, the inclination to accumulate
truncal body fat is associated with metabolic complications,
which occur at a lower BMI than in European/North
American populations [21, 29].
Safety evaluation in this study found that rimonabant
20mg was generally well tolerated in the Asian study
population. The most common adverse events reported with
an incidence ≥2% in the rimonabant group were upper
respiratory tract infection, nausea, diarrhea, dyspepsia, vom-
iting,dizziness,depression,anxiety,insomnia,hyperhidrosis,
palpitations, and fatigue. In addition, a lower number of
patients discontinued treatment due to adverse events and
thisnumberwascomparablebetweenthe2treatmentgroups
(3.1% versus 2.8%, in rimonabant and placebo group, resp.).
Among neuropsychiatric events, depression (4.1%, n = 13)
and anxiety (3.8%, n = 12) were higher in the rimonabant
20mg compared to placebo (0.9%, n = 3 and 1.5%, n = 5).
A meta-analysis of randomized trials involving rimonabant
20mg/dayhasproposedthatrimonabantincreasestheriskof
psychiatric adverse events including depression and anxiety.
Patients were 2.5 and 3.0 times more likely to discontinue
rimonabant due to depression and anxiety [30]. An overview
of the RIO programme with rimonabant was published
recently, which reviewed and summarized the overall eﬃcacy
and side eﬀects of RIO trials including RIO-Europe, RIO-
North America, RIO-Lipids, and RIO-Diabetes [31]. The
vast majority of the test populations are western ethnics. The
overall TEAE-induced drug discontinuation rate was higher
in the rimonabant than the placebo groups either without
(13.6% versus 7.7%, resp.) or with diabetes (15.0% versus
5.5%, resp.). The reported AE of depression was increased
in the rimonabant group, either in all obese cohort (3.9%
versus 1.7%, resp.) or in diabetes programme (2.5% versus
1.4%, resp.). The TEAE-induced drug discontinuation rate
in RIO-Asia seems to be much lower than that of other RIO
trials. Although the RIO-Asia has relatively a smaller sample
size and shorter duration than other RIO trials, the reported
AE of depression rate is still signiﬁcantly increased in the
rimonabant group in Asian population. Hence, monitoring
of rimonabant-induced psychiatric adverse events is
essential.
The endocannabinoid system (ECS), encompassing
endocannabinoids including anandamide and 2-arachi-
donoylglycerol (2-AG), two cannabinoid receptors, type
1 (CB1) and type 2 (CB2), and enzymes responsible
for endogenous ligand synthesis (phospholipase D) and
degradation (fatty acid amide hydrolase (FAAH)), is
a complex physiological system involved in metabolic
homeostasis such as modulating energy ﬂuxes and nutrients
regulation [32]. Recently, substantial clinical evidence
revealed that CB1 antagonists might result in risks of severe
psychiatric problems, including depression, anxiety, and
stress disorders, especially in those with underlying or
susceptible psychological problems. These ﬁndings have
made rimonabant (SR14176A), the ﬁrst CB1 inverse agonist
approved and launched in Europe in 2006, withdrawn from
the market in 2008, and thereof, several CB1 target-related
candidates including taranabant (MK-0364) and otenabant
(CP-945598) were suspended at the late clinical development
stage (phase III). In the meanwhile, increased evidence
indicates that CB1 receptors present in the peripheral tissue,
includingfatandliver,mightregulatefoodintakeandenergy
b a l a n c ea se ﬀectively as those present in the central nervous
system (CNS) [33]. This provides a rationale for develop-
ment of peripherally preferred or restricted CB1 antagonists
which possess minimized CNS adverse reactions and pre-
serve antiobesity eﬀects. Recently, this strategy of developing
CB1 antagonists without penetrating blood-brain barrier
(BBB) was found to meet with a certain degree of success.
Suﬃcient weight-reduction eﬃcacy and less CNS toxic
proﬁle have been observed with romonabant-mimicking
analogues acting exclusively on peripheral CB1 receptors
[34]. However, these compounds have been tested only in
animals.
5. Conclusion
The RIO-ASIA study of 9-month duration conﬁrmed the
eﬃcacy of rimonabant 20mg on weight reduction in the
Asian population. Besides the favourable eﬀect on weight,
signiﬁcant improvements were also observed in waist cir-
cumference, HDL-cholesterol, and triglycerides. The drug
was associated with a good safety proﬁle in the Asian study
population, which was consistent with the pattern observed
in the Caucasian population. However, in patients with
a history of psychiatric disorder, especially those with a
past history of depression, the usage of rimonabant is not
recommended owing to mild yet considerable increase of10 Journal of Obesity
psychiatric untoward side eﬀects observed in this trial as
well as other such similar trials. In addition, the psychiatric
status of patients taking rimonabant has to be monitored
regularly, preferably using a practical risk evaluation form
such as the Columbia classiﬁcation algorithm of suicide
assessment (C-CASA) [35]. Perceptively, to avoid untoward
CNS side eﬀects in drug discovery for the intervention
of the endocannabinoids system, an appealing strategy of
development of peripherally restricted and highly CB1/CB2
selective antagonists may be desired. Some compounds
of this kind have been shown to have promising results
in lowering propensity to pass the blood-brain barrier
with preserved weight-reducing eﬀects in DIO mice [36,
37]. Another peripheral-acting CB1 neutral antagonist
has been shown to have weight-independent eﬀects on
improving cardiometabolic risks and fatty liver in mouse
models of obesity [38]. However, the clinical eﬃcacy and
safety of these new antiobesity compounds are yet to be
seen.
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